MAP2K7 and neoplasm: Moreover, trametinib (conversely named GSK1120212) was shown to decrease Ras/MEK/ERK pathway activation and CD44 expression, resulting in a beneficial clinical response in patients (the effect was seen in 11 out of 17 patients), a decrease in tumor volume and tumor downstaging (Figure 4; Uppaluri et al., 2017).